How potent is the anti-inflammatory effect of this megastigmane glycoside?

The anti-inflammatory potency is classified as weak based on standard pharmacological criteria, with an IC50 exceeding 100 µM in preclinical cell-based assays — a threshold that most drug discovery programs would not prioritize for further development. For comparison, clinically relevant anti-inflammatory compounds typically exhibit IC50 values in the nanomolar to low micromolar range, making this compound significantly less potent than established therapeutics or even more active Vitex constituents like casticin.

Which plants contain (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside?

This compound has been isolated from plants within the genus Vitex (family Lamiaceae), which includes species such as Vitex trifolia and Vitex negundo, native to tropical and subtropical Asia, Africa, and the Mediterranean. It occurs as a minor secondary metabolite alongside other megastigmane glycosides, iridoids, and flavonoids; a structurally related compound has also been identified in apple (Malus domestica) leaves, suggesting broader distribution across flowering plants.

Are there any clinical trials on this compound?

No clinical trials of any design — randomized, observational, or pilot — have been conducted on (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside as of the available published literature. All evidence is restricted to in vitro phytochemical isolation and bioactivity screening studies, which represent very early-stage preclinical research and cannot be used to make evidence-based health claims for human use.

Is (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside safe to consume?

There are no published toxicological studies, safety assessments, or human exposure data for this isolated compound, making it impossible to characterize its safety profile with confidence. While Vitex genus plant extracts containing this compound among many other constituents have a traditional use history suggesting general tolerability, isolated glycosides can behave differently pharmacologically and toxicologically than whole-plant preparations, and no safe dose range for this specific compound has been established.

How does (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside contribute to Vitex supplement effectiveness compared to other megastigmanes?

(3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside is one of several megastigmane glycosides found in Vitex species that work synergistically to support the plant's bioactivity. While it demonstrates weak anti-inflammatory effects in isolation (IC50 > 100 µM), it likely functions as part of a broader phytochemical matrix alongside compounds like (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-on. The collective action of multiple megastigmanes in whole Vitex extracts may provide greater efficacy than individual isolated compounds alone.

What is the difference between in vitro anti-inflammatory data and real-world effectiveness for this megastigmane glycoside?

In vitro studies show (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside inhibits inflammatory pathways at high concentrations (IC50 > 100 µM), but this weak activity has not been confirmed in animal models or human clinical trials. The gap between laboratory results and biological efficacy is significant—compounds active in test tubes at high doses may not reach sufficient concentrations in human tissues to produce measurable effects. Until validated through in vivo research, claims about this specific compound's anti-inflammatory benefits in supplement form remain speculative.

Does the glycoside form of this megastigmane affect how your body processes it compared to non-glycosylated versions?

The β-D-glucopyranoside structure attached to (3S,4R)-dihydroxy-7,8-dihydro-β-ionone is a conjugated sugar moiety that may influence absorption, metabolism, and bioavailability in the digestive system. Glycosylated compounds require enzymatic deconjugation by gut microbiota or intestinal enzymes before the aglycone (parent compound) can be absorbed, potentially reducing bioavailability or altering tissue distribution. This structural feature distinguishes it from hypothetical non-glycosylated forms and may explain why whole Vitex extracts are used traditionally rather than isolated aglycones.

(3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside

(3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside is a megastigmane-class terpenoid glycoside whose anti-inflammatory activity is attributed to inhibition of pathways associated with inflammatory mediator production, consistent with related Vitex megastigmanes targeting NO, iNOS, and NF-κB signaling. Preclinical in vitro assays report observable but weak inhibitory activity with an IC50 exceeding 100 µM, placing it among the least potent anti-inflammatory phytochemicals characterized from Vitex isolate studies.

Category: Compound Evidence: 1/10 Tier: Preliminary

(3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside — Hermetica Encyclopedia

Origin & History

This megastigmane glycoside is a minor secondary metabolite isolated from plants within the genus Vitex (family Lamiaceae/Verbenaceae), which are distributed across tropical and subtropical regions of Asia, Africa, and the Mediterranean basin. Vitex species such as Vitex trifolia and Vitex negundo grow in warm, seasonally dry environments and have been cultivated and harvested in traditional medicine systems for centuries. The compound is extracted from plant material — typically leaves or aerial parts — using polar solvents such as methanol or ethanol, followed by chromatographic separation techniques including XAD-2 resin column chromatography and HPLC.

Historical & Cultural Context

Vitex species, the genus from which this compound is isolated, have a rich history in traditional medicine spanning Ayurveda, Traditional Chinese Medicine, and Mediterranean folk medicine, where preparations of Vitex negundo and Vitex agnus-castus were employed for inflammatory conditions, pain, female hormonal regulation, and fever management. In Ayurvedic medicine, Vitex negundo (Nirgundi) leaves were applied topically as poultices and taken internally as decoctions for arthritis and joint inflammation, with the bioactive attribution historically ascribed to the whole plant matrix rather than individual phytochemicals. The isolation and structural characterization of megastigmane glycosides such as this compound represents a modern phytochemical lens applied retrospectively to these traditional uses, and no historical text specifically references this glycoside by name or structure. The compound's identification is therefore a product of late 20th and early 21st century analytical phytochemistry rather than a traditionally recognized active principle.

Health Benefits

- **Anti-inflammatory Activity**: Demonstrates measurable inhibition of inflammatory pathways in vitro, with an IC50 > 100 µM; the activity, while statistically observable, is classified as weak and has not been validated in animal models or human subjects.
- **Structural Contribution to Vitex Bioactivity**: As a co-occurring megastigmane alongside (9R)-O-β-D-glucopyranosyloxy-2,5-megastigmen-4-one, it may contribute to the cumulative anti-inflammatory profile of Vitex extracts through additive effects with iridoids, flavonoids, and other terpenoids present in the same matrix.
- **Potential NF-κB Pathway Modulation**: Related megastigmane glycosides in Vitex species are associated with downregulation of NF-κB signaling, which governs transcription of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α; this compound shares structural features that make analogous activity plausible but unconfirmed.
- **Possible COX-2 and iNOS Inhibition**: By structural analogy with characterized Vitex megastigmanes, inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) is a mechanistically plausible but experimentally unverified benefit for this specific stereoisomer.
- **Phytochemical Marker Utility**: Its stereochemically defined structure (3S,4R configuration) serves as a chemotaxonomic marker for quality authentication of Vitex plant material, supporting the standardization of botanical extracts used in traditional and integrative medicine contexts.

How It Works

The compound belongs to the megastigmane class of terpenoid glycosides, characterized by a C13 ionone skeleton with hydroxyl substituents at C-3 and C-4 in the (3S,4R) stereochemical configuration and a β-D-glucopyranose moiety attached via an O-glycosidic bond at the C-4 hydroxyl. In preclinical anti-inflammatory assays, the compound exhibits inhibitory activity consistent with suppression of pro-inflammatory mediator production, though the precise molecular targets for this exact stereoisomer have not been elucidated. Structurally analogous megastigmane glycosides isolated from Vitex species have been shown to inhibit LPS-induced nitric oxide production in macrophage cell lines, suppress iNOS and COX-2 protein expression, and attenuate NF-κB nuclear translocation, suggesting these are the most likely mechanistic nodes for this compound as well. The glucopyranose moiety may modulate membrane permeability and cellular uptake, influencing the compound's effective intracellular concentration and its ability to reach cytosolic inflammatory signaling targets.

Scientific Research

The entirety of available evidence for this compound derives from phytochemical isolation studies and in vitro bioactivity screening, with no peer-reviewed animal studies or human clinical trials identified in the literature. The compound has been co-reported in studies characterizing megastigmane glycosides from Vitex species, where its anti-inflammatory activity was assessed in cell-based assays — most likely LPS-stimulated macrophage models — yielding an IC50 exceeding 100 µM, a threshold widely regarded in pharmacognosy as indicative of weak rather than therapeutically meaningful potency. A structurally related compound, 3,4-dihydroxy-7,8-dihydro-β-ionone 3-O-β-D-glucopyranoside, has been identified from apple (Malus domestica) leaves without detailed mechanistic or efficacy characterization, further underlining the scarcity of functional data across this compound class. The overall evidence base is rated very low quality by contemporary standards; no dose-response relationships, bioavailability parameters, or in vivo pharmacokinetic data have been published for this specific glycoside.

Clinical Summary

No clinical trials — randomized controlled or otherwise — have been conducted on (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside as an isolated compound or as a defined fraction of any botanical extract. All bioactivity data originate from in vitro screening assays, which represent the earliest stage of the preclinical drug or nutraceutical development pipeline and carry no direct translational weight for human health claims. The compound's weak potency profile (IC50 > 100 µM) further reduces its prioritization as a clinical development candidate relative to more potent co-occurring Vitex constituents such as casticin or agnuside. Confidence in any health-related claims for this specific compound is extremely low, and its mention in nutritional or supplement contexts should be understood as descriptive phytochemistry rather than evidence-based efficacy.

Nutritional Profile

As a pure isolated secondary metabolite, (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside does not possess a nutritional profile in the conventional macronutrient or micronutrient sense. Its molecular weight is approximately 390 g/mol (C19H32O8), comprising a terpenoid aglycone (dihydroxy-dihydro-β-ionone, C13 skeleton) conjugated to a β-D-glucopyranose sugar unit. It occurs as a minor secondary metabolite within Vitex plant material alongside primary phytochemicals including iridoid glycosides (agnuside, aucubin), flavonoids (casticin, luteolin, vitexin), diterpenes, and essential oils; its absolute concentration in plant tissue has not been quantified. Bioavailability is expected to be influenced by intestinal β-glucosidase activity, which can cleave the glycosidic bond to release the aglycone, a common fate for plant-derived glycosides, though this has not been experimentally confirmed for this compound.

Preparation & Dosage

- **Research Isolation Form**: Isolated via sequential methanolic or ethanolic extraction of Vitex plant material, followed by liquid-liquid partitioning and column chromatography (e.g., Sephadex LH-20, silica gel, or XAD-2 resin); this process yields research-grade pure compound not available in commercial supplement form.
- **Whole Plant Extract (Traditional)**: Vitex species are traditionally prepared as aqueous decoctions or hydroethanolic tinctures of dried leaves and aerial parts; no standardization to this specific glycoside is practiced or documented.
- **Effective Dose (Preclinical Reference Only)**: In vitro anti-inflammatory activity observed at concentrations above 100 µM; no translation to human-equivalent doses is possible without pharmacokinetic data.
- **Commercial Supplement Context**: Not available as a standalone ingredient; Vitex agnus-castus extracts standardized to 0.5% agnuside or 0.6% aucubin are the closest commercial analogs, but these are not standardized to megastigmane glycoside content.
- **Timing and Administration**: No recommendations exist; as a glycoside, enzymatic hydrolysis in the gastrointestinal tract prior to absorption is anticipated, but the aglycone's activity and absorption profile are undocumented.

Synergy & Pairings

No experimentally validated synergistic combinations have been reported for this compound specifically; however, within the Vitex phytochemical matrix, megastigmane glycosides co-occur with iridoids (aucubin, agnuside) and flavonoids (casticin, luteolin) that independently target overlapping anti-inflammatory pathways including NF-κB, COX-2, and cytokine release, raising the possibility of additive or synergistic effects within whole-plant extracts. Structural analogy with other terpenoid glycosides that demonstrate enhanced anti-inflammatory potency when combined with flavonoids via complementary enzymatic inhibition (e.g., iNOS suppression by terpenoids combined with COX-2 inhibition by flavonoids) provides a plausible mechanistic rationale for synergy within Vitex extracts, though this is not directly demonstrated for this compound. No named commercial stack pairings or formulated combination products incorporating this glycoside are documented in the literature.

Safety & Interactions

No toxicological studies, safety assessments, or adverse event data have been published specifically for (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside, reflecting its status as a research-isolated phytochemical that has never entered clinical or commercial use as an isolated ingredient. General safety inference from Vitex genus extracts suggests tolerability at traditional use doses, but such extrapolation to a purified glycoside fraction is scientifically unjustified without dedicated toxicology data. No drug interaction studies exist; however, given the anti-inflammatory mechanistic context (potential COX-2, NF-κB involvement), theoretical caution with concurrent use of NSAIDs, corticosteroids, or immunosuppressants could be considered purely hypothetically. Pregnancy and lactation safety is entirely unknown, and given the hormonal activity reported for Vitex genus preparations broadly, use during pregnancy or lactation should not be undertaken without medical supervision.